| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
178,600,000 |
| Market
Cap: |
692.97(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6736 - $4.76 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 10.8 |
| Insider 6 Months : 10.8 |
| Insider 3/6 Months : 21.3 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Precigen is a clinical-stage biopharmaceutical company improving gene and cell therapies. Co. is utilizing proprietary technology platforms to develop product candidates designed to diseases in its therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Co. is developing its clinical programs, including: PRGN-3005, PRGN-3006, and PRGN-3007, which are built on its UltraCAR-T platform; PRGN-2009 and PRGN-2012, which are based on its AdenoVerse immunotherapy platform; and AG019, which is built on its ActoBiotics platform. In addition, Co. has completed a Phase 1 study of INXN-4001, a non-viral triple-effector plasmid DNA, which is built on its UltraVector platform.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
60,221 |
60,221 |
60,221 |
23,745,141 |
| Total Buy Value |
$235,938 |
$235,938 |
$235,938 |
$20,422,264 |
| Total People Bought |
4 |
4 |
4 |
6 |
| Total Buy Transactions |
7 |
7 |
7 |
10 |
| Total Shares Sold |
6,984,279 |
6,984,279 |
6,984,279 |
7,080,965 |
| Total Sell Value |
$25,428,689 |
$25,428,689 |
$25,428,689 |
$25,565,016 |
| Total People Sold |
2 |
2 |
2 |
2 |
| Total Sell Transactions |
5 |
5 |
5 |
6 |
| End Date |
2025-08-07 |
2025-05-06 |
2024-11-05 |
2023-11-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kindler Jeffrey B |
Director |
– • – |
2025-09-30 |
4 |
S |
$3.38 |
$361,109 |
D/D |
(106,837) |
346,070 |
|
-26% |
|
| Kirk Randal J |
|
– • • |
2025-09-30 |
4 |
S |
$3.41 |
$6,170,964 |
I/I |
(1,809,667) |
14,597,161 |
|
-26% |
|
| Kindler Jeffrey B |
Director |
– • – |
2025-09-29 |
4 |
S |
$3.60 |
$243,083 |
D/D |
(67,523) |
452,907 |
|
-14% |
|
| Tennant Phil |
Chief Commercial Officer |
• – – |
2025-09-29 |
4 |
B |
$3.58 |
$21,480 |
D/D |
6,000 |
65,031 |
2.74 |
14% |
|
| Shah Rutul R |
Chief Operating Officer |
• – – |
2025-09-26 |
4 |
B |
$3.40 |
$6,800 |
D/D |
2,000 |
405,959 |
2.74 |
18% |
|
| Thomasian Harry Jr. |
Chief Financial Officer |
• – – |
2025-09-26 |
4 |
B |
$3.42 |
$10,027 |
D/D |
2,932 |
468,626 |
2.74 |
18% |
|
| Thomasian Harry Jr. |
Chief Financial Officer |
• – – |
2025-09-25 |
4 |
B |
$3.62 |
$29,988 |
D/D |
8,284 |
465,694 |
2.74 |
19% |
|
| Kirk Randal J |
Director |
– • • |
2025-09-19 |
4 |
S |
$3.68 |
$13,236,563 |
I/I |
(3,596,892) |
8,520,537 |
|
-10% |
|
| Kirk Randal J |
Director |
– • • |
2025-09-18 |
4 |
S |
$3.86 |
$5,416,970 |
I/I |
(1,403,360) |
12,117,429 |
|
-9% |
|
| Kirk Randal J |
Director |
– • • |
2025-09-17 |
4 |
OE |
$0.00 |
$0 |
I/I |
17,385,257 |
82,164,767 |
|
- |
|
| Agee Nancy H |
Director |
– • – |
2025-09-04 |
4 |
B |
$4.60 |
$69,000 |
D/D |
15,000 |
217,841 |
2.39 |
-9% |
|
| Agee Nancy H |
Director |
– • – |
2025-08-28 |
4 |
B |
$4.65 |
$49,491 |
D/D |
10,645 |
202,841 |
2.39 |
-9% |
|
| Agee Nancy H |
Director |
– • – |
2025-08-19 |
4 |
B |
$3.20 |
$49,152 |
D/D |
15,360 |
192,196 |
2.39 |
29% |
|
| Agee Nancy H |
Director |
– • – |
2025-07-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
126,760 |
176,836 |
|
- |
|
| Shah Rutul R |
Chief Operating Officer |
• – – |
2025-05-16 |
4 |
D |
$1.45 |
$84,239 |
D/D |
(58,096) |
403,959 |
|
- |
|
| Shah Rutul R |
Chief Operating Officer |
• – – |
2025-05-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
174,460 |
462,055 |
|
- |
|
| Tennant Phil |
Chief Commercial Officer |
• – – |
2025-05-16 |
4 |
D |
$1.45 |
$33,305 |
D/D |
(22,969) |
59,031 |
|
- |
|
| Tennant Phil |
Chief Commercial Officer |
• – – |
2025-05-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
66,441 |
82,000 |
|
- |
|
| Sabzevari Helen |
President and CEO |
• • – |
2025-05-16 |
4 |
D |
$1.45 |
$755,775 |
D/D |
(521,224) |
3,317,022 |
|
- |
|
| Sabzevari Helen |
President and CEO |
• • – |
2025-05-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,079,137 |
3,838,246 |
|
- |
|
| Thomasian Harry Jr. |
Chief Financial Officer |
• – – |
2025-05-16 |
4 |
D |
$1.45 |
$74,589 |
D/D |
(51,441) |
457,410 |
|
- |
|
| Thomasian Harry Jr. |
Chief Financial Officer |
• – – |
2025-05-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
154,475 |
508,851 |
|
- |
|
| Lehr Donald P. |
Chief Legal Officer |
• – – |
2025-05-16 |
4 |
D |
$1.45 |
$79,896 |
D/D |
(55,101) |
681,649 |
|
- |
|
| Lehr Donald P. |
Chief Legal Officer |
• – – |
2025-05-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
165,468 |
736,750 |
|
- |
|
| Gupta Vinita D |
Director |
– • – |
2025-03-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
87,412 |
576,240 |
|
- |
|
644 Records found
|
|
Page 1 of 26 |
|
|
0.28 (6.73%) 
